Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2024

Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2024

DelveInsight’s, “Neoantigen-based Personalized Cancer therapeutic Vaccines – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Neoantigen-based Personalized Cancer therapeutic Vaccines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neoantigen-based Personalized Cancer therapeutic Vaccines Understanding

Neoantigen-based Personalized Cancer therapeutic Vaccines: Overview

Tumors are lump of tissue that form due to uncontrollable cell growth and replace normal healthy tissues with abnormal tissues. Tumors can be benign (non-cancerous) and malignant that can spread to different organs and lymphatic system of the body through a process known as metastasis. Malignant tumors are associated with high morbidity and mortality across the globe and constitute considerable threat for human beings. The traditional treatment for malignant tumors is based on radiation therapy, surgery, chemotherapy, and others each with their own pros and cons.

Neoantigen-based Personalized Cancer therapeutic Vaccines has emerged as a new tumor immunotherapy approach for eliminating malignant tumors. Neoantigens are specific non-autologous proteins which are generated by non-synonymous mutations in tumorous cell genome. Neoantigens are highly immunogenic and are different from traditional tumor associated antigens (TAA) as they are not expressed in normal cells. These antigens can activate CD4+ and CD8+ T cells to generate immune response which have the potential to become new targets for tumor immunotherapy. Tumor vaccines targeting neoantigens predominantly include of nucleic acid, tumor cell, dendritic cell-based and synthetic long peptide vaccines.

Symptoms

Symptoms for malignant tumors vary widely depending upon the part of the body which is affected. However, some common symptoms associated with malignant tumors include abnormal bumps, unexplained fever, unintentional weight loss, loss of appetite, night sweats, and weakness or numbness in the body muscles.

Diagnosis

Diagnosing for malignant tumors requires physical assessment to look for abnormalities that may indicate the presence of cancer as well as certain tests which include blood, and urine test, biopsy, and imaging tests such as MRI, CT-scan, and PET scan analysis.

Treatment

Although different treatment regimens are available for malignant tumors which include surgery, radiation therapy, targeted therapy, and chemotherapy each one of them are associated with some pros and cons. For instance, there is always a chance for recurrence after administration of these treatments. However, efficacy of these treatments can be increased with the combination of these traditional therapies with emerging neoantigen- based personalized cancer therapy can induce strong specific immune response and elicit stable therapeutic effects. Currently, the drugs for this therapy are in clinical trials and is anticipated to exhibit promising results.

Neoantigen-based Personalized Cancer therapeutic Vaccines Emerging Drugs Chapters

This segment of the Neoantigen-based Personalized Cancer therapeutic Vaccines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neoantigen-based Personalized Cancer therapeutic Vaccines Emerging Drugs

• Tedopi (OSE2101): OSE Immunotherapeutics

OSE’ advanced drug candidate, Tedopi (OSE2101), is a proprietary combination of nine optimized neo-epitopes and one epitope giving universal helper T cell response targeting T cell activation. The drug is in phase III clinical trials NSCLC and in phase II for pancreatic cancer. The drug is a cytotoxic T lymphocyte stimulant and has been proved beneficial for HLA-A2 positive individuals in NSCLC, a key receptor for cytotoxic T-immune response.

• NEO-PV-01: Neon Therapeutics, Inc. (BioNtech)

Neon’s neoantigen vaccine candidate NEO-PV-01 in combination with nivolumab is currently being evaluated for the treatment of advanced or metastatic melanoma, smoking associated NSCLC, and bladder cancer. The drug is in phase I b of clinical trials and has demonstrated prolonged and consistent improvements in progression-free survival (PFS) and overall survival (OS) in melanoma patients.

Further product details are provided in the report……..

Neoantigen-based Personalized Cancer therapeutic Vaccines: Therapeutic Assessment

This segment of the report provides insights about the different Neoantigen-based Personalized Cancer therapeutic Vaccines drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Neoantigen-based Personalized Cancer therapeutic Vaccines

There are approx. 10+ key companies which are developing the therapies for Neoantigen-based Personalized Cancer therapeutic Vaccines. The companies which have their Neoantigen-based Personalized Cancer therapeutic Vaccines drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, OSE Immunotherapeutics and others.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Neoantigen-based Personalized Cancer therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neoantigen-based Personalized Cancer therapeutic Vaccines: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neoantigen-based Personalized Cancer therapeutic Vaccines therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neoantigen-based Personalized Cancer therapeutic Vaccines drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Neoantigen-based Personalized Cancer therapeutic Vaccines R&D. The therapies under development are focused on novel approaches to treat/improve Neoantigen-based Personalized Cancer therapeutic Vaccines.

Neoantigen-based Personalized Cancer therapeutic Vaccines Report Insights

• Neoantigen-based Personalized Cancer therapeutic Vaccines Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neoantigen-based Personalized Cancer therapeutic Vaccines Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neoantigen-based Personalized Cancer therapeutic Vaccines drugs?
• How many Neoantigen-based Personalized Cancer therapeutic Vaccines drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neoantigen-based Personalized Cancer therapeutic Vaccines?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neoantigen-based Personalized Cancer therapeutic Vaccines therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neoantigen-based Personalized Cancer therapeutic Vaccines and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• OSE Immunotherapeutics
• Neon Therapeutics, Inc. (BioNtech)
• Genocea Biosciences
• Hangzhou Neoantigen Therapeutics

Key Products

• Tedopi (OSE2101)
• NEO-PV-01
• Gen-009
• iNeo-Vac-P01